| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.38 mm | 3.38 mm | 3.38 mm | 3.38 mm | 3.38 mm | 3.38 mm |
| Cash burn (monthly) | 88.94 k | (no burn) | 1.47 mm | 777.64 k | 919.53 k | 886.03 k |
| Cash used (since last report) | 248.24 k | n/a | 4.10 mm | 2.17 mm | 2.57 mm | 2.47 mm |
| Cash remaining | 3.13 mm | n/a | -715.50 k | 1.21 mm | 813.70 k | 907.21 k |
| Runway (months of cash) | 35.2 | n/a | -0.5 | 1.6 | 0.9 | 1.0 |
| 13F holders | Current |
|---|---|
| Total holders | 25 |
| Opened positions | 20 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 227.85 mm |
| Total shares | 9.55 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Phoenix Biotech Sponsor | 5.30 mm | $0.00 |
| Fitzgerald Securities Cantor | 905.00 k | $8.97 mm |
| Cowen And | 638.60 k | $43.55 mm |
| Periscope Capital | 591.50 k | $40.34 mm |
| Atalaya Capital Management | 425.00 k | $37.83 mm |
| MMCAP International Inc. SPC | 375.00 k | $25.58 mm |
| Shaolin Capital Management | 267.60 k | $18.25 mm |
| Linden Advisors | 250.00 k | $20.00 mm |
| Q Global Advisors | 170.79 k | $12.00 k |
| Clear Street | 143.93 k | $10.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Dec 24 | YK Bioventures Opportunities GP I | Common Stock | Sell | Dispose S | Yes | No | 0.06 | 2,998,908 | 179.93 k | 13,005,169 |
| 12 Dec 24 | YK Bioventures Opportunities GP I | Common Stock | Sell | Dispose S | Yes | No | 0.07 | 1,614,541 | 113.02 k | 16,004,077 |
| 11 Dec 24 | YK Bioventures Opportunities GP I | Common Stock | Sell | Dispose S | Yes | No | 0.08 | 1,343,801 | 107.50 k | 17,618,618 |
| 10 Dec 24 | YK Bioventures Opportunities GP I | Common Stock | Sell | Dispose S | Yes | No | 0.09 | 1,570,947 | 141.39 k | 18,962,419 |
| 9 Dec 24 | YK Bioventures Opportunities GP I | Common Stock | Sell | Dispose S | Yes | No | 0.11 | 850,543 | 93.56 k | 20,533,366 |
| 6 Dec 24 | YK Bioventures Opportunities GP I | Common Stock | Sell | Dispose S | Yes | No | 0.12 | 1,236,874 | 148.42 k | 21,383,909 |
| 2 Dec 24 | Shami Patel | Stock Option Common Stock | Grant | Acquire A | No | No | 0.0951 | 127,500 | 12.13 k | 127,500 |
| 2 Dec 24 | Atwood Brian G | Stock Option Common Stock | Grant | Acquire A | No | No | 0.1 | 254,000 | 25.40 k | 254,000 |
| 2 Dec 24 | Christopher B Ehrlich | Stock Option Common Stock | Grant | Acquire A | No | No | 0.1 | 1,275,000 | 127.50 k | 1,275,000 |
